CAJ | 학술논문

目的：探讨血清糖类抗原125（CA125）在Her-2阳性乳腺癌患者术后生物化疗疗效监测的评估价值。方法回顾性分析以蒽环类及紫杉类为基础联合曲妥珠单抗﹙Herceptin﹚治疗44例Her-2阳性乳腺癌患者术后血清CA125的变化。根据2000年实体瘤疗效评价标准（RECIST）标准分有效组（OR组）及无效组（NR组），通过分析两组治疗前后CA125的变化及下降比率绘制ROC曲线评估其对生物化疗疗效的价值。结果与治疗前相比，所有患者治疗后CA125血清水平显著下降（P＜0.05）。治疗前有效组及无效组间CA125无明显差异（P＞0.05）；治疗后有效组血清CA125水平显著下降（P＜0.05），而无效组治疗前后无显著性差异（P＞0.05）。采用治疗前后CA125下降比率绘制ROC曲线，其曲线下面积为0.701。结论CA125在Her-2阳性乳腺癌患者术后生物化疗疗效有一定预测作用，且有较高的敏感性及特异性。
목적：탐토혈청당류항원125（CA125）재Her-2양성유선암환자술후생물화료료효감측적평고개치。방법회고성분석이은배류급자삼류위기출연합곡타주단항﹙Herceptin﹚치료44례Her-2양성유선암환자술후혈청CA125적변화。근거2000년실체류료효평개표준（RECIST）표준분유효조（OR조）급무효조（NR조），통과분석량조치료전후CA125적변화급하강비솔회제ROC곡선평고기대생물화료료효적개치。결과여치료전상비，소유환자치료후CA125혈청수평현저하강（P＜0.05）。치료전유효조급무효조간CA125무명현차이（P＞0.05）；치료후유효조혈청CA125수평현저하강（P＜0.05），이무효조치료전후무현저성차이（P＞0.05）。채용치료전후CA125하강비솔회제ROC곡선，기곡선하면적위0.701。결론CA125재Her-2양성유선암환자술후생물화료료효유일정예측작용，차유교고적민감성급특이성。
Objective To evaluate the role of CA125 in predicting response during biochemotherapy after sur-gery in Her-2 positive breast cancer patients. Method CA125 level changes in 44 cases of Her-2 positive breast cancer during biochemotherapy (base on paclitaxel or anthraceneand with Herceptin) after surgery were analyzed ret-rospectively. All patients were divided into responsive group (OR group) or unresponsive group (NR group) accord-ing to RECIST criteria of the year of 2000. ROC curve was plotted based on the decrease rate of CA125 to evaluate its role in predicting response. Result CA125 level decreased significantly in all patients and in the OR group after biochemotherapy (P<0.05), while it showed no significant differences in OR vs NR group before biochemotherapy (P>0.05), as well as in the NR group before vs after biochemotherapy (P>0.05). AUC of CA125 was 0.701. Conclu-sion CA125 may predict the response in Her-2 positive breast cancer during biochemotherapy, with superior specific-ity and sensitivity.